

Summit Therapeutics plc

("Summit" or the "Company")

SUMMIT THERAPEUTICS TO PARTICIPATE IN SUNTRUST ROBINSON HUMPHREY'S 2016 ORPHAN DRUG DAY

Oxford, UK, 17 February 2016 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and *Clostridium difficile* infection, announces that management will participate in one on one meetings at SunTrust Robinson Humphrey's 2016 Orphan Drug Day, taking place 23 February 2016 in New York City.

A copy of the presentation will be available through the Investors section on the Company's website, www.summitplc.com.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, *Clostridium difficile* infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)

Tel: +44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP

(Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 77148 7900

N+1 Singer

(Broker)
Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

Peckwater PR

(Financial public relations, UK)
Tarquin Edwards

Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)
Chris Erdman

Tel: +1 781 235 3060
cerdman@macbiocom.com

-END-